| Entry |
|
|---|
| Name |
Nadolol (JP18/USP/INN);
Corgard (TN) |
|---|
| Product |
|
|---|
| Generic |
NADOLOL (Alembic Pharmaceuticals Limited), NADOLOL (Alembic Pharmaceuticals), NADOLOL (American Health Packaging), NADOLOL (Amneal Pharmaceuticals NY LLC), NADOLOL (Aurobindo Pharma Limited), NADOLOL (Bayshore Pharmaceuticals LLC), NADOLOL (BluePoint Laboratories), NADOLOL (Bryant Ranch Prepack), NADOLOL (Bryant Ranch Prepack), NADOLOL (Bryant Ranch Prepack), NADOLOL (Bryant Ranch Prepack), NADOLOL (Bryant Ranch Prepack), NADOLOL (Bryant Ranch Prepack), NADOLOL (Cipla USA), NADOLOL (Coupler LLC), NADOLOL (Exelan Pharmaceuticals), NADOLOL (Major Pharmaceuticals), NADOLOL (Marlex Pharmaceuticals), NADOLOL (VGYAAN Pharmaceuticals LLC), NADOLOL (Zydus Lifesciences Limited), NADOLOL (Zydus Pharmaceuticals USA) |
|---|
| Formula |
C17H27NO4
|
|---|
| Exact mass |
309.1940
|
|---|
| Mol weight |
309.40
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01464 beta-Adrenergic receptor antagonist (Beta blocker)
DG01653 Antiarrhythmics
DG01806 Class II antiarrhythmic agent
DG03231 Antihypertensive
|
|---|
| Remark |
|
|---|
| Efficacy |
Antiarrhythmic, Antihypertensive, Vasodilator, beta-Adrenergic receptor antagonist |
|---|
| Disease |
|
|---|
| Comment |
Propranolol derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04261 | Adrenergic signaling in cardiomyocytes |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C07 BETA BLOCKING AGENTS
C07A BETA BLOCKING AGENTS
C07AA Beta blocking agents, non-selective
C07AA12 Nadolol
D00432 Nadolol (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Beta-adrenergic Blocking Agents
Non-Selective
Nadolol
D00432 Nadolol (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
212 Antiarrhythmic agents
2123 Beta blockers
D00432 Nadolol (JP18/USP/INN)
214 Antihypertensives
2149 Others
D00432 Nadolol (JP18/USP/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01464 beta-Adrenergic receptor antagonist (Beta blocker)
D00432 Nadolol
DG01653 Antiarrhythmics
DG01806 Class II antiarrhythmic agent
D00432 Nadolol
DG03231 Antihypertensive
D00432 Nadolol
Drug classes [BR:br08332]
Cardiovascular agent
DG03231 Antihypertensive
D00432 Nadolol
DG01653 Antiarrhythmics
D00432 Nadolol
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRB1
D00432 Nadolol (JP18/USP/INN) <JP/US>
ADRB2
D00432 Nadolol (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00432 Nadolol
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 22
1 O2a O 25.1300 -25.3400
2 C1b C 26.3200 -24.6400
3 C1c C 27.5800 -25.3400
4 C1b C 28.7700 -24.6400
5 O1a O 27.5800 -26.8100
6 N1b N 29.9600 -25.3400
7 C1d C 31.2200 -24.6400
8 C1a C 32.4800 -25.3400
9 C1a C 31.2200 -23.4500
10 C1a C 32.4800 -23.9400
11 C8y C 25.1300 -26.7400
12 C8y C 23.9400 -27.4400
13 C8y C 23.9400 -28.8400
14 C8x C 25.1300 -29.5400
15 C8x C 26.3200 -28.8400
16 C8x C 26.3200 -27.4400
17 C1x C 22.7276 -26.7400
18 C1y C 21.5151 -27.4400
19 C1y C 21.5151 -28.8400
20 C1x C 22.7276 -29.5400
21 O1a O 20.2840 -26.7290
22 O1a O 20.2840 -29.5510
BOND 23
1 1 2 1
2 2 3 1
3 3 4 1
4 3 5 1
5 4 6 1
6 6 7 1
7 7 8 1
8 7 9 1
9 7 10 1
10 1 11 1
11 11 12 2
12 12 13 1
13 13 14 2
14 14 15 1
15 15 16 2
16 11 16 1
17 12 17 1
18 17 18 1
19 18 19 1
20 19 20 1
21 13 20 1
22 18 21 1 #Up
23 19 22 1 #Up
|
|---|
